Repligen Co. (NASDAQ:RGEN) Holdings Decreased by Pitcairn Co.

Pitcairn Co. lessened its stake in Repligen Co. (NASDAQ:RGEN) by 6.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,584 shares of the biotechnology company’s stock after selling 318 shares during the period. Pitcairn Co.’s holdings in Repligen were worth $682,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Champlain Investment Partners LLC boosted its holdings in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after acquiring an additional 850,345 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after purchasing an additional 425,061 shares during the period. Bank of New York Mellon Corp boosted its stake in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in shares of Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after purchasing an additional 199,322 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after buying an additional 121,305 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Repligen stock opened at $142.58 on Monday. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average price of $140.26 and a 200 day moving average price of $143.27.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share. On average, equities analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of research analyst reports. Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. Stephens reissued an “overweight” rating and set a $170.00 target price on shares of Repligen in a research note on Tuesday, July 30th. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.